{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T04:10:36Z","timestamp":1793333436047,"version":"4.5.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2011,9]]},"DOI":"10.1016\/j.amjcard.2011.04.015","type":"journal-article","created":{"date-parts":[[2011,6,22]],"date-time":"2011-06-22T03:36:56Z","timestamp":1308713816000},"page":"682-690","source":"Crossref","is-referenced-by-count":333,"title":["Eicosapentaenoic Acid Ethyl Ester (AMR101) Therapy in Patients With Very High Triglyceride Levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] Trial)"],"prefix":"10.1016","volume":"108","clinical-trial-number":[{"clinical-trial-number":"nct01047683","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Harold E.","family":"Bays","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christie M.","family":"Ballantyne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.","family":"Kastelein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan L.","family":"Isaacsohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rene A.","family":"Braeckman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paresh N.","family":"Soni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2011.04.015_bib1","first-page":"69","article-title":"Fenofibrate for the treatment of type IV and V hyperlipoproteinemias: a double-blind, placebo-controlled multicenter US study","volume":"11","author":"Goldberg","year":"1989","journal-title":"Clin Ther"},{"key":"10.1016\/j.amjcard.2011.04.015_bib2","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1586\/14779072.6.3.391","article-title":"Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications","volume":"6","author":"Bays","year":"2008","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.1016\/j.amjcard.2011.04.015_bib3","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1161\/01.CIR.0000133317.49796.0E","article-title":"Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines","volume":"110","author":"Grundy","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2011.04.015_bib4","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.atherosclerosis.2006.02.012","article-title":"Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: a systematic review","volume":"189","author":"Balk","year":"2006","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.amjcard.2011.04.015_bib5","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1093\/ajcn\/76.2.326","article-title":"The n-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid increase systemic arterial compliance in humans","volume":"76","author":"Nestel","year":"2002","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.amjcard.2011.04.015_bib6","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1681\/ASN.V10102177","article-title":"Eicosapentanoic acid reduces plasma levels of remnant lipoproteins and prevents in vivo peroxidation of LDL in dialysis patients","volume":"10","author":"Ando","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.amjcard.2011.04.015_bib7","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0029-7844(00)00988-1","article-title":"Eicosapentaenoic acid effect on hyperlipidemia in menopausal Japanese women","volume":"96","author":"Kurabayashi","year":"2000","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.amjcard.2011.04.015_bib8","doi-asserted-by":"crossref","first-page":"144","DOI":"10.2337\/dc06-1179","article-title":"Purified eicosapentaenoic acid reduces small dense LDL, remnant lipoprotein particles, and C-reactive protein in metabolic syndrome","volume":"30","author":"Satoh","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1016\/j.amjcard.2011.04.015_bib9","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1161\/circ.106.25.3143","article-title":"Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection Evaluation, and Treatment of High Blood cholesterol in Adults (Adult Treatment Panel III) final report","volume":"106","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2011.04.015_bib10","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0272-2712(18)30645-0","article-title":"The Centers for Disease Control-National Heart, Lung and Blood Institute Lipid Standardization Program: an approach to accurate and precise lipid measurements","volume":"9","author":"Myers","year":"1989","journal-title":"Clin Lab Med"},{"key":"10.1016\/j.amjcard.2011.04.015_bib11","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s00769-002-0537-0","article-title":"The College of American Pathologists laboratory accreditation program","volume":"7","author":"Rabinovitch","year":"2002","journal-title":"Accred Qual Assur"},{"key":"10.1016\/j.amjcard.2011.04.015_bib12","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0022-2275(20)41577-9","article-title":"A comprehensive evaluation of the heparin-manganese precipitation procedure for estimating high density lipoprotein cholesterol","volume":"19","author":"Warnick","year":"1978","journal-title":"J Lipid Res"},{"key":"10.1016\/j.amjcard.2011.04.015_bib13","unstructured":"Manual of Laboratory Operations: LRC Program, Vol. 1: Lipid and Lipoprotein Analysis. DHEW Publication No. (NIH) 75-628. May 1974. Revised version issued October, 1982."},{"key":"10.1016\/j.amjcard.2011.04.015_bib14","doi-asserted-by":"crossref","first-page":"861","DOI":"10.3945\/jn.108.103861","article-title":"Dietary alpha-linolenic acid, EPA, and DHA have differential effects on LDL fatty acid composition but similar effects on serum lipid profiles in normolipidemic humans","volume":"139","author":"Egert","year":"2009","journal-title":"J Nutr"},{"key":"10.1016\/j.amjcard.2011.04.015_bib15","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1093\/ajcn\/71.5.1085","article-title":"Purified eicosapentaenoic and docosahexaenoic acids have differential effects on serum lipids and lipoproteins, LDL particle size, glucose, and insulin in mildly hyperlipidemic men","volume":"71","author":"Mori","year":"2000","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.amjcard.2011.04.015_bib16","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1194\/jlr.M200282-JLR200","article-title":"Omega-3 fatty acid supplementation accelerates chylomicron triglyceride clearance","volume":"44","author":"Park","year":"2003","journal-title":"J Lipid Res"},{"key":"10.1016\/j.amjcard.2011.04.015_bib17","first-page":"a20007","article-title":"Effects of eicosapentaenoic acid, docasahexaenoic acid, and olive oil on cardiovascular disease risk factors [abstract 20007]","volume":"122","author":"Schaefer","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2011.04.015_bib18","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/j.1753-4887.2010.00272.x","article-title":"Long-chain omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid dose-dependently reduce fasting serum triglycerides","volume":"68","author":"Musa-Veloso","year":"2010","journal-title":"Nutr Rev"},{"key":"10.1016\/j.amjcard.2011.04.015_bib19","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1016\/j.clinthera.2007.07.018","article-title":"Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g\/d to simvastatin 40 mg\/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study","volume":"29","author":"Davidson","year":"2007","journal-title":"Clin Ther"},{"key":"10.1016\/j.amjcard.2011.04.015_bib20","doi-asserted-by":"crossref","first-page":"122","DOI":"10.4065\/mcp.2009.0397","article-title":"Effects of prescription omega-3-acid ethyl esters on non\u2013high-density lipoprotein cholesterol when coadministered with escalating doses of atorvastatin","volume":"85","author":"Bays","year":"2010","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.amjcard.2011.04.015_bib21","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0021-9150(99)00267-1","article-title":"Omacor in familial combined hyperlipidemia: effects on lipids and low density lipoprotein subclasses","volume":"148","author":"Calabresi","year":"2000","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.amjcard.2011.04.015_bib22","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/S0828-282X(09)70715-9","article-title":"Canadian Cardiovascular Society\/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult\u20142009 recommendations","volume":"25","author":"Genest","year":"2009","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.amjcard.2011.04.015_bib23","doi-asserted-by":"crossref","first-page":"811","DOI":"10.2337\/dc08-9018","article-title":"Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation","volume":"31","author":"Brunzell","year":"2008","journal-title":"Diabetes Care"},{"key":"10.1016\/j.amjcard.2011.04.015_bib24","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1001\/jama.2009.1619","article-title":"Major lipids, apolipoproteins, and risk of vascular disease","volume":"302","author":"Di Angelantonio","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2011.04.015_bib25","doi-asserted-by":"crossref","first-page":"41F","DOI":"10.1016\/j.amjcard.2008.04.018","article-title":"Review of the evidence for the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk marker","volume":"101","author":"Corson","year":"2008","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2011.04.015_bib26","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1007\/s11883-009-0050-6","article-title":"Darapladib and atherosclerotic plaque: should lipoprotein-associated phospholipase A2 be a therapeutic target?","volume":"11","author":"McCullough","year":"2009","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.amjcard.2011.04.015_bib27","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1161\/01.CIR.0000143377.53389.C8","article-title":"Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern Germany","volume":"110","author":"Koenig","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2011.04.015_bib28","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1161\/01.ATV.0000240406.89440.0c","article-title":"Lipoprotein-associated phospholipase A2 and prognosis after myocardial infarction in the community","volume":"26","author":"Gerber","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.amjcard.2011.04.015_bib29","series-title":"The Johns Hopkins Textbook of Dyslipidemia","article-title":"Fish oils in the treatment of dyslipidemia and cardiovascular disease","author":"Bays","year":"2010"},{"key":"10.1016\/j.amjcard.2011.04.015_bib30","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S0140-6736(07)60527-3","article-title":"Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis","volume":"369","author":"Yokoyama","year":"2007","journal-title":"Lancet"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914911015992?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914911015992?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,11,26]],"date-time":"2021-11-26T03:18:25Z","timestamp":1637896705000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914911015992"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["S0002914911015992"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2011.04.015","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2011,9]]}}}